Harrow, Inc. heads into the back half of 2026 with a striking split in conviction — the co-founders bought the stock aggressively after a steep earnings selloff, while short sellers have quietly added to already elevated positions.
The insider buying is the sharpest signal from the past month. After HROW fell roughly 22% following its Q1 earnings print on May 12, founder and CEO Mark Baum purchased 10,000 shares at $30.20 — a $302,000 commitment — and founder-CFO Andrew Boll added 3,500 shares at $29.90. Two independent directors followed days later with purchases at $31. The cluster of buying, all in the $29–$31 range, came directly into the post-earnings weakness and represents the most concentrated insider accumulation the company has seen in recent history.
Short positioning tells the opposite story, and the tension between the two camps is the defining setup this week. Short interest has crept up to 17.97% of the free float — roughly 6.7 million shares — rising about 1.3% over the past week and nearly 6% over the past month. That is a persistently high level, and the direction is still upward. Borrow availability runs at 39.5%, well below the midpoint of a normal range, meaning the lending pool is meaningfully constrained. The 52-week trough for availability was 20.1%, so there is still room to tighten further. Cost to borrow remains low at under 1%, which suggests shorts are not yet being squeezed out by economics — they are holding their ground cheaply. The ORTEX short score has climbed steadily to 79.5, its highest point in the trailing 30-day window, reflecting the combination of heavy positioning and tightening borrow conditions.
Options traders are offering no corroboration to the bear case. The put/call ratio has fallen to 0.18, close to its 52-week low of 0.17 and well below the year's high of 0.44. That reading flags an unusually call-heavy options market — not the profile of investors bracing for further downside. The divergence between the options book and the short interest register is genuine and worth tracking: one side of the market is positioned for recovery, the other is not.
The Street remains broadly constructive but has been trimming targets to reflect the Q1 disappointment. Cantor Fitzgerald maintained its Overweight rating while cutting its target from $91 to $88 after the earnings release. BTIG held its Buy and $63 target. B. Riley had already moved its target from $74 to $65 in early April. The mean target across covered analysts is $67.75, roughly double the current price of $33.46 — implying the Street collectively sees meaningful upside, though the gap also reflects how far the stock has fallen from analyst expectations set earlier in the year. The bull case centres on new product launches, including MELT, and management's confidence in its $350M–$365M full-year revenue guidance. Bears point to weak Vevye demand, high-deductible plan headwinds, and a Q1 revenue miss that shook near-term confidence.
Earnings history adds a sobering backdrop. The May 12 print produced a one-day drop of nearly 22% and the stock gave back roughly 19% over the following five days — a punishing reaction that explains both the insider buying at lower levels and the short sellers' reluctance to cover. The next earnings date is August 7. Between now and then, the relevant watch points are whether short interest continues its slow drift higher, whether borrow availability tightens below the 30% threshold, and whether the call-heavy options positioning begins to shift as the summer progresses.
See the live data behind this article on ORTEX.
Open HROW on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
